Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (OMER)
NASDAQ:OMER
OMER Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.95 - $13.60
Previous CloseN/A
Volume193.12K
Average Volume (3M)1.31M
Market Cap
$272.53M
Enterprise Value$906.07M
Total Cash (Recent Filing)$52.41M
Total Debt (Recent Filing)$203.88M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 14, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding67,126,785
10 Day Avg. Volume2,075,450
30 Day Avg. Volume1,307,033
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.32
Enterprise Value/Revenue2.20K
Enterprise Value/Gross Profit-4.36K
Enterprise Value/Ebitda-5.79
Forecast
1Y Price Target
$9.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe company provided details on a significant potential asset acquisition/licensing agreement that would provide OMER with an upfront payment of up to $150MM-$200MM, substantial development, regulatory and sales-based milestones and sales royalties.
Product EfficacyResults of those analyses showed clinically meaningful and statistically significant improvements in survival associated with narsoplimab treatment.
Regulatory ApprovalThe submission of marketing authorization to the European Medicines Agency for narsoplimab is seen as a significant step for OMER, potentially leading to re-rating driven by approvals and pipeline reinvestment.
Bears Say
Regulatory Approval ChallengesThere is skepticism of FDA approval of narsoplimab given the limited clinical dataset from open-label trials, the long drawn-out process since the CRL, and the lack of new clinical data to support a positive outcome.
Regulatory DelaysThe PDUFA date for Narsoplimab was extended by 3 months following the submission of new info in response to a request by FDA.
Omeros News
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $2.95 and its highest was $13.60 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $272.53M.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Aug 14, 2025 which is in 2 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on May 15, 2025. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.58.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -0.5.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 67,126,785 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of -$0.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -18.481%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in OMER
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (117.39% Upside)
$9.00 (117.39% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 39.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.83%
12-Months-Change
Fundamentals
Return on Equity
87.26%
Trailing 12-Months
Asset Growth
-46.25%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corporation (OMER) is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various medical conditions. The company operates primarily in the field of inflammation, coagulopathies, and central nervous system disorders. Omeros' lead product, Omidria, is used in cataract and lens replacement surgery to prevent intraoperative miosis and reduce postoperative ocular pain. Additionally, the company is engaged in multiple clinical-stage development programs targeting conditions such as complement-mediated diseases and addiction.
OMER Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a cautious optimism. While there are significant positive developments, particularly with debt restructuring and progress toward narsoplimab approval, the increase in net loss, decline in OMIDRIA sales, and pausing of certain clinical programs present notable challenges.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$9.00
▲(117.39% Upside)
Technical Analysis
Zevra Therapeutics
―
Relay Therapeutics
―
Ginkgo Bioworks Holdings
―
Upstream Bio, Inc.
―
Ownership Overview
4.53%
Insiders
8.20% Mutual Funds
0.07% Other Institutional Investors
77.22% Public Companies and
Individual Investors